Michela Rondoni

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

Jelena Jovanović, Joannah Score, Katherine Waghorn et al. · Blood · 2007 · 204 citations · Full text

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study

Michele Baccarani, Daniela Cilloni, Michela Rondoni et al. · Haematologica · 2007 · 191 citations · Full text

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Haematologica · 2007 · 186 citations · Full text

Engineering, Mixed-phenotype Acute Leukemia, Pathology +18

Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the <scp>I</scp>talian network on secondary leukemias

Luana Fianchi, Livio Pagano, Alfonso Piciocchi et al. · American Journal of Hematology · 2015 · 121 citations · Full text

Hematological Malignancy, Shorter Latency, Therapy‐related Myeloid Neoplasms +13

Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas

Pier Paolo Piccaluga, Giovanni Martinelli, Michela Rondoni et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2004 · 70 citations · Full text

Hematological Malignancy, Myeloid Sarcomas, Oncology +14